Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.38 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.38 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.38 |
| ▸ | ESRRB | O95718 | 3/20 | 0.38 |
| ▸ | ESRRG | P62508 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374099 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1MAPTPKMKHK | |
| SCHEMBL19358312 | 0.81 | HTR3A (0.50) | KDM4EALDH1A1MAPT | |
| SCHEMBL29478226 | 0.81 | HTR3A (0.50) | KDM4EALDH1A1MAPT | |
| SCHEMBL22171249 | 0.81 | MAPT (0.51) | KDM4EALDH1A1MAPTPKMKHK | |
| Hydrochloric Acid SCHEMBL22165259 | 0.79 | MAPT (0.50) | KDM4EALDH1A1MAPTPKMKHK | |
| SCHEMBL21361441 | 0.78 | MAPT (0.49) | KDM4EALDH1A1MAPTPKMALK | |
| SCHEMBL29937495 | 0.78 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPTPKM | |
| SCHEMBL28867024 | 0.78 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPTPKM | |
| SCHEMBL28767962 | 0.76 | KDM1A (0.36) | ALDH1A1MAPTKCNH2 | |
| SCHEMBL27195824 | 0.76 | KDM4E (0.50) | KDM4EALDH1A1MAPTPKMKHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116869-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2026-04-30 | — | — | US | disclosed |
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| EP-4442317-A2 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | Novartis AG (CH) | 2024-10-09 | — | — | EP | disclosed |
| EP-3971177-B1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2024-06-26 | — | — | EP | disclosed |
| EP-3971177-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| CN-114014844-A | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | 诺华股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-109641871-B | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | 诺华股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3487851-B1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2021-10-20 | — | — | EP | disclosed |
| US-20210155606-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2021-05-27 | — | — | US | disclosed |
| US-10947218-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20200299265-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2020-09-24 | — | — | US | disclosed |
| US-10710980-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190161474-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2019-05-30 | — | — | US | disclosed |
| CN-109641871-A | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | 诺华股份有限公司 | 2019-04-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710980-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR2B, ACVR1B | KDM4E 449/4885ALDH1A1 632/4885MAPT 2662/4885 |
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR1, ACVR1B | KDM4E 347/4885ALDH1A1 589/4885MAPT 2439/4885 |
| US-10947218-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR2B, ACVR1B | KDM4E 372/4885ALDH1A1 799/4885MAPT 2337/4885 |
| US-20200299265-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR2B, ACVR1B | KDM4E 372/4885ALDH1A1 799/4885MAPT 2337/4885 |
| US-20190161474-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR2B, ACVR1B | KDM4E 449/4885ALDH1A1 632/4885MAPT 2662/4885 |
| US-20260116869-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR1, ACVR1B | KDM4E 1080/4885ALDH1A1 561/4885MAPT 4635/4885 |
| US-20210155606-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR1, ACVR1B | KDM4E 347/4885ALDH1A1 589/4885MAPT 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.